Clinical Trials

Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

237 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT07000084 2026-04-07

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05839119 2026-04-02

TASUC-Neo

Phase 1 Terminated

2 enrolled

Urinary Bladder Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT01104350 2026-03-05

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Phase 1 Completed

19 enrolled

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

25 enrolled

Urinary Bladder Neoplasms

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

46 enrolled

Urinary Bladder Neoplasms

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

30 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Recruiting

178 enrolled

Carcinoma, Transitional Cell

NCT07296705 2025-12-22

HARBOR

25 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT05975307 2025-12-01

BCIRT-01

71 enrolled

Urinary Bladder Neoplasms

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

57 enrolled

DermatologicGenitourinarySarcoma

Carcinoma, Transitional Cell

NCT03093909 2025-11-10

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT01495676 2025-10-10

GETUGV04

Phase NA Terminated

69 enrolled 9 charts

Urinary Bladder Neoplasms

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

30 enrolled

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

46 enrolled

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT06571708 2025-09-02

NeoSTOP-IT

36 enrolled

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

12 enrolled

Urinary Bladder Neoplasms, Neoplasms

NCT01261728 2025-08-08

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

57 enrolled

Carcinoma, Transitional Cell

NCT02885974 2025-07-28

BLAST

Phase 1 Completed

22 enrolled

Urinary Bladder Neoplasms

NCT04574960 2025-07-20

NAUTICAL

14 enrolled

Urinary Bladder Neoplasms

NCT07043972 2025-07-20

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

55 enrolled

Carcinoma, Transitional Cell

NCT04865939 2025-07-17

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

132 enrolled

Phase 1/2 Not yet recruiting

Urothelial Cancer of Renal Pelvis

NCT07064863 2025-07-17

BCG-TIME

31 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04179162 2025-06-13

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

54 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07019220 2025-06-13

COBRA

47 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04602078 2025-04-24

AUREA

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Phase 1 Recruiting

10 enrolled

Muscle Invasive Bladder Cancer

NCT06257017 2025-04-04

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

20 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05024734 2025-03-11

GAIN INST

34 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

210 enrolled

Urinary Bladder Neoplasms

NCT00627432 2025-02-18

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

44 enrolled

Urinary Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

41 enrolled